Abstract
A total of 50 consecutive adult patients with newly diagnosed aggressive non-Hodgkin’s lymphoma were treated with a weekly alternating combination chemotherapy schedule, BEMOP/CA, including bleomycin, etoposide, methotrexate, vincristine, cyclophosphamide and Adriamycin. Two-thirds of the patients were over 60 years old or had stage 4 disease. Clinical remission was achieved in 56% of cases. The 3-year survival is 53% (95% confidence interval, 39 – 66%). The presence of B symptoms and a serum albumin value of <33 g/l at presentation were poor prognostic indicators for survival in a multivariate proportional-hazards model. Overall, the response rate and survival for this group of patients with intermediate- and high-grade lymphomas is similar to results previously reported. The BEMOP/CA treatment was brief (16 weeks) and associated with a low fatal toxicity (one early death and one late fatality from Pneumocystis pneumonia), and the drug costs are equivalent to those for eight cycles of CHOP.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 27 March 1995 / Accepted: 5 September 1995
Rights and permissions
About this article
Cite this article
Bower, M., Brock, C., Gulliford, T. et al. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. Cancer Chemother Pharmacol 38, 106–109 (1996). https://doi.org/10.1007/s002800050455
Issue Date:
DOI: https://doi.org/10.1007/s002800050455